Literature DB >> 27579488

Interpretation of idarucizumab clinical trial data based on spontaneous reports of dabigatran adverse effects in the French pharmacovigilance database.

Albert Trinh-Duc1, Agnès Lillo-Le Louët2, Eric Tellier1, Thibault Viard1, Grégoire Le Gal3, David M Smadja4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27579488     DOI： 10.1016/j.thromres.2016.08.014

Source DB:  PubMed          Journal:  Thromb Res        ISSN： 0049-3848            Impact factor:   3.944


× No keyword cloud information.
  3 in total

1.  The Use of Idarucizumab for Dabigatran Reversal in Clinical Practice: A Case Series.

Authors:  Pavel Goriacko; Vicken Yaghdjian; Issam Koleilat; Mark Sinnett; Harshal Shukla
Journal:  P T       Date:  2017-11

2.  Evidence for Idarucizumab (Praxbind) in the Reversal Of the Direct Thrombin Inhibitor Dabigatran: Review Following the RE-VERSE AD Full Cohort Analysis.

Authors:  Timothy C Hutcherson; Nicole E Cieri-Hutcherson; Rajvi Bhatt
Journal:  P T       Date:  2017-11

Review 3.  Current status of oral anticoagulant reversal strategies: a review.

Authors:  Aranyak Rawal; Devarshi Ardeshna; Sheharyar Minhas; Brandon Cave; Uzoma Ibeguogu; Rami Khouzam
Journal:  Ann Transl Med       Date:  2019-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.